
    
      The primary objective is to assess the short and long term tolerability of ipilimumab in
      combination with osimertinib. The secondary objective is to assess efficacy of osimertinib in
      combination with ipilimumab. Ipilimumab will be given for a total of four doses and
      osimertinib will be given until treatment discontinuation criteria is met. Ipilimumab at the
      assigned dose level every 3 weeks for four doses in combination with once daily osimertinib.
    
  